Cambrex Corp. has completed the acquisition of Avista Pharma Solutions, a contract development, manufacturing, and testing organization, from Ampersand Capital Partners. The transaction expands the company’s integrated small molecule CDMO services across the entire drug lifecycle.
 
Avista’s four sites in Durham, NC, Longmont, CO, Agawam, MA and Edinburgh, Scotland, UK will be integrated into Cambrex’s global network, as well as the company’s service offerings ranging from API and drug product development and cGMP manufacturing to stand-alone analytical, microbiology testing and solid state sciences.
 
“Acquiring Avista adds a full complement of early stage development capabilities to Cambrex’s larger scale capabilities for both APIs and finished dosage forms. We are excited to start off 2019 integrating Avista into Cambrex’s global network of facilities. Adding Avista today and Halo Pharma in September significantly increases our customer base and funnel of projects, provides significant cross selling opportunities and allows us to offer an integrated service offering for most small molecules from the pre-clinical stage through the commercial stage,” said Steve Klosk, president and chief executive officer of Cambrex.
 
In September 2018, Cambrex acquired Halo Pharma, adding formulation development and finished dosage manufacturing capabilities. With the acquisition of Avista, Cambrex now operates 12 facilities around the globe and employs approximately 2,000 people.